Galapagos @ EULAR 2021

The EULAR European Congress of Rheumatology comprises the major event in the calendar of world rheumatology. The EULAR 2021 Virtual Congress will address a wide range of topics including clinical, translational and basic science.
Galapagos is excited to be top sponsor at EULAR 2021 and to support two symposia and Meet the Expert session. We are looking forward to meeting you virtually @ EULAR 2021!

Trending Topics in RA

The Role of JAK Inhibitors in Rheumatoid Arthritis

by Jaime Calvo-Alén, Spain | June 2021

Assessment of Patient Perspectives in Rheumatoid Arthritis: Emerging Roles and Impacts

by Roberto Caporali, Italy  | June 24, 2021

Emerging Data on COVID-19 in Rheumatology

by Pedro Machado, UK | June 24, 2021

Difficult-to-Treat Rheumatoid Arthritis: Definitions and Management

by Elena Nikiphorou, UK | June 24, 2021

Help us serve
5000 coffees!

All proceeds will go to French patient organisation ANDAR

This is how it works:

1. You order a coffee - It’s free!

2. You enjoy your drink and invite your colleagues

3. We will donate to ANDAR


Enjoy your coffee.

By ordering your coffee you have supported the national French patient organization for RA, ANDAR. If you want to hear more about our products, services and developments please stay in touch with us.

Fundraising Counter

Goal: 5.000 coffees served

Coffee Limit
The target has reached

Welcome to Galapagos @ EULAR 2021

Watch the invitations from Prof. Gossec, Prof. Dougados, Prof. Huizinga and Prof. Burmester to the two industry symposia and Meet The Experts session sponsored by Galapagos.


Continuing evolution of RA patient care as we adapt to a changing environment

In this symposium, Prof. Laure Gossec (Pitié-Salpêtrière Hospital, Paris), Prof. Peter Nash (Griffith University, Brisbane) and Prof. Peter Taylor (University of Oxford) will discuss how treatment and holistic care for patients with rheumatoid arthritis has adapted to the new environment, and how to incorporate close monitoring when making remote treatment decisions in a patient-centric approach.

<h4>Prof. Laure Gossec</h4>

Prof. Laure Gossec

Pitié-Salpêtrière Hospital and Pierre & Marie Curie University, Paris, France



Laure Gossec, MD, PhD, is Professor of Rheumatology at Sorbonne Université and Pitié-Salpêtrière Hospital, Paris, France. She divides her time between a clinical position, where she mainly treats patients with inflammatory arthritis, and a teaching and research position.
Her main research interests are treatment outcomes and epidemiology. Her research focusses on patient-reported outcomes and quality of life, as well as e-health and big data, in psoriatic arthritis, spondyloarthritis and rheumatoid arthritis.

Prof. Gossec is a past-chair of the epidemiology standing committee of the European League Against Rheumatism (EULAR). She is one of the editors of the journal Joint Bone Spine and has authored more than 350 peer-reviewed manuscripts.

<h4>Prof. Peter Taylor</h4>

Prof. Peter Taylor

University of Oxford, Oxford, UK



Peter C. Taylor holds the Norman Collison chair of musculoskeletal sciences at the University of Oxford and is a fellow of St Peter’s College, Oxford. He is head of experimental rheumatology at the Botnar Research Centre within the Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences.

He studied preclinical medical sciences at Gonville & Caius College at the University of Cambridge, Cambridge, UK, and his first degree was a BA (Cantab) in physiology in 1982. He subsequently studied clinical medicine at the University of Oxford and graduated in 1985 with BM and BCh degrees. He was awarded a PhD in 1996 from the University of London, London, UK, for research on the pathogenesis of arthritis. In addition, he was elected a fellow of the Royal College of Physicians in 2000 and a distinguished member of the British Society for Rheumatology in 2016.
Prof. Taylor has clinical interests in inflammatory arthritis and research interests in targeted therapies.

<h4>Prof. Peter Nash</h4>

Prof. Peter Nash

School of Medicine, Griffith University, Brisbane, Australia



Peter Nash is Professor at the School of Medicine, Griffith University, Associate Professor at the Department of Medicine, University of Queensland, Brisbane, Australia, and Director of the Rheumatology Research Unit on the Sunshine Coast. Prof. Nash has chaired the Professional Affairs Committee and the Therapeutics Committee of the Australian Rheumatology Association and serves on their Scientific Advisory Committee. He has also chaired musculoskeletal panels for the NHMRC. He is a former member of the Therapeutics Committee of the Australia and New Zealand Bone and Mineral Society. He remains on the International Steering Committee for the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). He is on the editorial board of Annals of the Rheumatic Diseases and RMD Open.
Prof. Nash and his group at the Rheumatology Research Unit have been involved with pivotal registration clinical trials for all modern targeted synthetic and biologic therapies. He has published more than 200 peer-reviewed papers and five book chapters, and acts as reviewer for a number of journals. He has recently been recognised as the Australian rheumatology research leader, with the most citations in the top 20 journals in rheumatology over the past 5 years. His special interests include metabolic bone disease and novel therapeutics.

EULAR 2021 Industry Symposium June 2

Continuing evolution of RA patient care as we adapt to a changing environment


Exploring the role of JAK-inhibitors within the diverging RA treatment landscape

Join Prof. Maxime Dougados (University of Paris), Prof. Rieke Alten (Charité University Hospital), Prof. Kevin Winthrop (Oregon Health and Science University) and Prof. Ernest Choy (Cardiff University) for a live discussion on the impact of the burden of RA on patients and how selecting the most appropriate advanced therapy can positively impact patients’ daily lives. This symposium will also examine how evolutions in mechanism of action may impact efficacy and safety profiles of different treatments. Get your questions answered by our expert faculty: this session includes a live Q&A.

<h4>Prof. Maxime Dougados</h4>

Prof. Maxime Dougados

Cochin Hospital University of Paris, France



Maxime Dougados is Professor of rheumatology at Paris University and Consultant at Cochin Hospital, Paris, France. He is also an executive board member of the Osteoarthritis Research Society International and a member of the French Society of Rheumatology, the American College of Rheumatology, the Morocco Society of Rheumatology and the Collège Français des Enseignants de Rhumatologie (COFER). He has acted as president and president-elect of the European League Against Rheumatism (EULAR) and president of COFER. Prof. Dougados’s research interests are focussed on measuring outcomes in rheumatic diseases, including inflammatory rheumatic diseases, osteoarthritis and bone diseases. He has published extensively on rheumatic diseases and is credited as an author on over 1000 articles. He has also served as an advisory editor for numerous rheumatology journals.

<h4>Prof. Rieke Alten</h4>

Prof. Rieke Alten

University Medicine Berlin, Germany



Rieke Alten has been head of the Department of Internal Medicine, Rheumatology, Clinical Immunology, Osteology at Schlosspark-Klinik, University Medicine Berlin since 1990, where she also serves as Director of the Rheumatology Research Centre.
She received her medical degrees from the Free University Berlin, Berlin, Germany. After graduating, she pursued immunology research at the Institute of Immunology, University of Zürich, Zürich, Switzerland.
Prof. Dr Alten has received board certification in internal medicine, rheumatology, physical therapy and rehabilitation medicine, and sports medicine.
Her research interests focus on the development and systematic evaluation of biological and immunomodulatory treatments for the rheumatic diseases.
She has been the lead and Principal Investigator for clinical trials of novel therapies in rheumatic diseases and has contributed to several investigator-initiated trials. She was a member of several data monitoring committees for new treatment compounds. She has published more than 200 original papers, book chapters and reviews.
Prof. Dr Alten is a member of the OMERACT Steering Committee of the Rheumatoid Arthritis Flare Group. She has served as a board member of the German Medical Association, the Institute for Approval of Drugs for the German Ministry of Health, the Kaiser Friedrich Foundation for postgraduate education in Germany and the German Society of Rheumatology. In 2020, she was appointed a member of the Steering Committee of the Cytokine Signalling Forum.

<h4>Prof. Ernest Choy</h4>

Prof. Ernest Choy

Cardiff University, Cardiff, UK



Ernest Choy is head of Rheumatology and Translational Research at the Division of Infection and Immunity and Director of the Cardiff Regional Experimental Arthritis Treatment and Evaluation (CREATE) Centre at Cardiff University School of Medicine, Cardiff, Wales. He is also Honorary Consultant Rheumatologist at the University Hospital of Wales, Cardiff, Wales, and Clinical Lead of the Welsh Arthritis Research Network (WARN). Previously, he was Reader and Director of the King’s Musculoskeletal Clinical Trials Unit at the Academic Department of Rheumatology, King’s College London, London, UK. He was also Director of Research and Development at King's College Hospital between 2003 and 2008.
His major research interest is the treatment of rheumatic diseases, focussing on the efficacy of new treatment strategies. Prof. Choy chaired the European League Against Rheumatism (EULAR) taskforce on developing recommendations for management and classification criteria for fibromyalgia in 2007. He has served as a clinical expert to the National Institute for Clinical Excellence in the UK and many pharmaceutical companies. He has published widely on treatments for rheumatic diseases in major medical journals, such as the New England Journal of Medicine. He frequently lecturers on the treatment of rheumatic diseases.

<h4>Prof. Kevin Winthrop</h4>

Prof. Kevin Winthrop

Oregon Health & Science University, Portland, USA



Kevin L. Winthrop is Professor of Public Health at the Oregon Health & Science University-Portland State University School of Public Health (OHSU-PSU SPH), and Professor of Infectious Diseases and Ophthalmology at the School of Medicine, Oregon Health & Science University.
Prof. Dr Winthrop received his undergraduate degree in biology from Yale University, New Haven, CT, USA, an MD from OHSU and a master's degree in public health from University California, Berkley, CA, USA. He completed his internal medicine residency training at Legacy Emanuel Hospital, Portland, OR, USA and an infectious disease epidemiology fellowship at the US Centers for Disease Control and Prevention (CDC). In 2006, Dr Winthrop returned to OHSU as Assistant Professor before progressing to his current appointment in 2018.
Dr Winthrop has co-authored over 300 publications, many regarding the epidemiologic and clinical aspects of opportunistic infections associated with immune-mediated inflammatory diseases, particularly those related to biologic immunosuppressive therapies.
As a primary or senior investigator in many clinical or epidemiologic studies in these fields, he has collaborated closely with the rheumatology community in the evaluation and prevention of opportunistic infections in that setting. In addition, he is also a member of the graduate faculty at OHSU where he mentors public health students, medical students and physicians in postgraduate training. At OHSU, he directs a national referral centre for chronic chest infections, and he serves as the medical consultant to the state of Oregon’s Tuberculosis Control Program.

EULAR 2021 Industry Symposium June 3

Exploring the role of JAK-inhibitors within the diverging RA treatment landscape.


JAK-inhibitor monotherapy for RA: Who, when and why

Join Prof. Gerd Burmester (Charité University Hospital, Berlin) and Prof. Tom Huizinga (Leiden University Medical Center) as they explain the efficacy and safety of JAK inhibitors as monotherapy for patients with moderate-to-severe RA, and discuss, using patient case studies, when and how to implement JAK inhibitor monotherapy in clinical practice. Get your questions answered by our expert faculty: this session includes a live Q&A.

<h4>Prof. Tom Huizinga</h4>

Prof. Tom Huizinga

Leiden University Medical Center, Netherlands



Tom W. J. Huizinga studied medicine at the University of Amsterdam, Amsterdam, The Netherlands, and received a PhD in medical sciences cum laude in 1989. He trained as a rheumatologist at Leiden University from 1991 to 1997 and went on to work there as a rheumatologist.
He became Professor of Rheumatology in 2000 and Chairman of the Department of Rheumatology in 2006. He was awarded the Carol-Nachman Prize in 2018.
Prof. Huizinga has been involved in numerous research projects and clinical trials, including more than 80 finished PhD projects and more than 800 peer-reviewed articles. The Department of Rheumatology at Leiden University is currently ranked highest in the world (
Prof. Huizinga’s research interests include translational and clinical rheumatology with a strong focus on pathogenesis. He was involved in the discovery of the relevance of anti-citrullinated peptide autoantibody responses for the diagnoses and development of rheumatoid arthritis and systemic lupus erythematosus.

<h4>Prof. Gerd Burmester</h4>

Prof. Gerd Burmester

Charité University Hospital, Berlin, Germany



Gerd R. Burmester is Professor of Medicine and Director of the Department of Rheumatology and Clinical Immunology at the Charité University Hospital, Free University and Humboldt University in Berlin, Germany. He earned his MD from Hannover Medical School, Hannover, Germany, and completed a residency at the Medical School of the University of Erlangen-Nuremberg, Erlangen, Germany. Prof. Burmester was awarded a postdoctoral fellowship at the Rockefeller University, and was a visiting scholar at the Hospital for Joint Diseases, Mount Sinai School of Medicine, New York City, NY, USA.
Prof. Burmester’s research interests include rheumatoid arthritis, Lyme borreliosis, immunotherapy, cellular activation mechanisms in inflammatory joint diseases and tissue engineering. 
Prof. Burmester has published more than 800 original and review articles in peer-reviewed journals such as Lancet, The New England Journal of Medicine, Annals of the Rheumatic Diseases and Arthritis and Rheumatology. He serves on several editorial boards, including the Journal of Rheumatology and Clinical Rheumatology, and is Associate Editor of Annals of the Rheumatic Diseases, the official journal of the European League against Rheumatism (EULAR). 
Prof. Burmester has been President of the German Society of Rheumatology and EULAR (amongst numerous other positions within EULAR) as well as President of the board of trustees of FOREUM, the Foundation for Research in Rheumatology. In 2019, he became a Master of the American College of Rheumatology and has received numerous awards, including the Jan van Breemen medal of the Dutch Society for Rheumatology and the Carol-Nachman Prize for Rheumatology.

Meet the experts June 4

JAK-inhibitor monotherapy for RA: Who, when and why?

Trending RA Topics to Watch @ EULAR 2021

Watch rheumatology experts discussing trending topics in RA and the related sessions @ EULAR 2021.

Prof. Pedro Machado, UK

Prof. Roberto Caporali, Italy

Prof. Jaime Calvo-Alén, Spain

Dr. Elena Nikiphorou, UK

Stay up to date!

I would like to receive informational and promotional communication via e-mail concerning Galapagos’ products, services and developments.

Download useful material about JAK-STAT & beyond

Teach JAK-STAT is a unique source of educational resources and downloadable presentations on JAK-STAT and beyond. Access valuable materials for your own self-knowledge, or to share with your peers.

Registrations for EULAR 2021 now open

The EULAR European Congress of Rheumatology comprises the major event in the calendar of world rheumatology.

More about…